PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report

1

SMARCA4-deficient undifferentiated cervical carcinoma is highly aggressive with poor prognosis and limited response to standard therapies.
2

A 9.8 cm cervical tumor was treated with the PRaG5.0 regimen, combining short-course SBRT, cadonilimab, GM-CSF, thymosin α1, and chemotherapy.
3

Initial treatment led to a significant tumor size reduction from 9.8 cm to 7.2 cm, with further reduction to 3.7 cm after sequential chemoimmunotherapy.
4

The patient experienced over 12 months of progression-free survival following the comprehensive treatment approach.
5

This case suggests that PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy may effectively manage large, resistant cervical tumors.

Frontiers In Immunology

by Zixin Li, Xuezhou Pang, Zhongyao Wang, Jing Wen, Yanli Zhao, Daiyuan Ma, Jianquan Yang
May 8, 2026

1